GE HealthCare Technologies (NASDAQ:GEHC) Issues Earnings Results

GE HealthCare Technologies (NASDAQ:GEHC) released its quarterly earnings data on Wednesday. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.04, FiscalAI reports. GE HealthCare Technologies had a net margin of 10.11% and a return on equity of 21.35%. The firm had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business posted $1.45 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. GE HealthCare Technologies updated its FY 2026 guidance to 4.950-5.150 EPS.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• GE HealthCare reported a strong quarter with $5.7B revenue (organic +4.8%), adjusted EPS $1.44 (excluding tariffs EPS would have grown ~11%), and $916M free cash flow, beating expectations.
• The company exited with a record backlog of $21.8B (book-to-bill ~1.06) and highlighted more than $7B in enterprise deals since the spin, supporting future revenue visibility.
• Tariff headwinds materially pressured margins—management cited ~$245M full-year EBIT tariff impact (~$0.43 EPS) and ~$100M tariff drag in Q4—though mitigation actions (supply shifts, Heartbeat) are underway.
• Innovation momentum remains a core driver with multiple NPIs on track (photon-counting CT, total-body PET, SIGNA MR, Vivid Pioneer) and an improving Flyrcado ramp (CMOs ~95% on-time delivery, ~220 weekly doses reported) with a $500M by 2028 revenue target.
• 2026 guidance is prudent—organic growth 3–4%, adjusted EPS $4.95–$5.15 (8–12% growth), adjusted EBIT ~15.8–16.1% and ~$1.7B FCF—with management explicitly taking a cautious stance on China, expecting a decline embedded in the plan.

GE HealthCare Technologies Trading Down 0.4%

Shares of GEHC stock opened at $82.31 on Friday. The company has a market cap of $37.49 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 2.46 and a beta of 1.08. GE HealthCare Technologies has a 1 year low of $57.65 and a 1 year high of $94.80. The stock’s 50 day simple moving average is $82.72 and its two-hundred day simple moving average is $77.50. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.37 and a quick ratio of 0.95.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Friday, January 9th will be given a dividend of $0.035 per share. The ex-dividend date is Friday, January 9th. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio is 2.89%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GEHC shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of GE HealthCare Technologies in a research note on Monday, December 29th. Piper Sandler increased their price objective on shares of GE HealthCare Technologies from $91.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Citigroup lifted their target price on GE HealthCare Technologies from $83.00 to $88.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $95.00 to $97.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Morgan Stanley raised their price target on GE HealthCare Technologies from $80.00 to $85.00 and gave the company an “equal weight” rating in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Hold” and a consensus target price of $92.50.

Institutional Trading of GE HealthCare Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Boston Partners purchased a new position in GE HealthCare Technologies during the third quarter worth $287,627,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of GE HealthCare Technologies by 17.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,432,374 shares of the company’s stock worth $633,271,000 after acquiring an additional 1,232,828 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in GE HealthCare Technologies during the 2nd quarter valued at about $58,388,000. AQR Capital Management LLC grew its holdings in GE HealthCare Technologies by 451.1% during the 3rd quarter. AQR Capital Management LLC now owns 864,732 shares of the company’s stock valued at $63,817,000 after purchasing an additional 707,810 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in GE HealthCare Technologies in the 2nd quarter worth about $44,027,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.